Sinopharm Group's declining ROCE trend is concerning. Increased capital investment without matching sales suggests long-term plays. High current liabilities to total assets ratio introduces risk. These trends indicate Sinopharm may not be a multi-bagger.
$恒生指数(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$荣昌生物(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $三叶草生物-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$维亚生物(01873.HK)$...
Sinopharm Group's low P/E ratio is due to investors' limited growth expectations, leading to a reduced stock price. The poor earnings outlook from analysts also contributes to its low P/E. These conditions may continue to hinder the share price.
Sinopharm Group is currently undervalued and it might be a good time to accumulate more holdings in the stock. The positive outlook on the horizon of the company's future seems not to be fully factored into the current share price.
The declining trend in Sinopharm Group's ROCE and the stock's 42% fall in the last five years doesn't inspire investor confidence. The article doesn't consider Sinopharm Group as a potential multi-bagger based on the present analysis.
$国药控股(01099.HK)$ It's dropping just because of morgamnstanley downgrades, which at best is right 3 out of 10 times. Dont listen to these analysts which have lots of vested interest. Chinese govt has a saying, polish your knives and make the kill when opportunity comes.... This company has lots of researchers on it and stay humble without bleating data unlike western counterparts. Wont be long before a breakthrough vaccine or medicine will come through with all the resources and financial muscle it has...
1
1
举报
Charstey :
I believe that a suitable vaccine will come out soon, and its decline is only temporary
$国药控股(01099.HK)$Price will fly near (*earning release) good time and price to pick up. 股价会在年报之前起飞。这价位入场不会错 🤑 Above are my personal point of view 以上是我个人看法
$国药控股(01099.HK)$$国药控股(ADR)(SHTDY.US)$this company should see a jump soon ⬆️ Covid19 vaccine now inuse In the U.A.E 应该很快跳涨的可能性。以批准在中东使用。 Above are base on personal point of view. 以上基于我个人的观点。
国药控股(ADR)股票讨论区
HSI Plunge Once Deepens to 620 Pts; Pharmas In Sell-off
Pharmaceuticals were sold off. $荣昌生物(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$三叶草生物-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $维亚生物(01873.HK)$ ...
It's dropping just because of morgamnstanley downgrades, which at best is right 3 out of 10 times. Dont listen to these analysts which have lots of vested interest. Chinese govt has a saying, polish your knives and make the kill when opportunity comes.... This company has lots of researchers on it and stay humble without bleating data unlike western counterparts. Wont be long before a breakthrough vaccine or medicine will come through with all the resources and financial muscle it has...
Stock watch ♻️
Above are my personal point of view
以上是我个人看法
Market Watch ♻️
专栏Stock watch 🔰
应该很快跳涨的可能性。以批准在中东使用。
Above are base on personal point of view.
以上基于我个人的观点。
暂无评论